Study suggests 90% of cancers have more to do with behavior than raw bad luck

Flying in the face of a January study in Science suggesting that two-thirds of cancers result from random cell mutations—i.e., bad luck—a new study in Nature points to behavioral factors (smoking, eating poorly, being exposed to pollution and the sun) as the culprit in nine of every 10.

The new study was conducted at Stony Brook Cancer Center on Long Island.

Speaking with BBC News about the study Dec. 17, co-author Yusuf Hannun, MD, director of the center, sums up the ramifications of the team’s findings in vivid terms: He compares engaging in the behavioral risk factors with playing Russian roulette.

“[M]aybe one in six will get cancer; that's the intrinsic bad luck,” says Hannun. “Now, what a smoker does is add two or three more bullets to that revolver. And now, they pull the trigger.

“There is still an element of luck, as not every smoker gets cancer, but they have stacked the odds against them[selves].

“From a public health point of view, we want to remove as many bullets as possible from the chamber.”

News article and videos on the BBC News website.

Study in Nature (behind paywall). 

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.